ANIP - רווח נקי למניה (EPS TTM) ANI Pharmaceuticals Inc

ANI Pharmaceuticals is expanding its portfolio through licensing agreements and contract outsourcing. The rolling annual EPS trend confirms this momentum, with the latest value recorded as 4.98. Business stability is underpinned by the production of generics and the premium Cortrophin Gel. Risks are minimized through the localization of raw materials, which protects the company from external geopolitical shocks.

This indicator serves as a critical filter during asset stress testing, allowing for the exclusion of overvalued companies facing excessive debt pressure. The metric calculates annual net income per common share, which, in a rolling earnings per share figure, reflects the actual efficiency of the compact development team at ANI Pharmaceuticals (ANIP), whose high decision-making speed converts directly into profit growth.